Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
13.6K
-
Shares change
-
0
-
Total reported value, excl. options
-
$307K
-
Price
-
$22.63
Significant Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q4 2023
1 filings reported holding AVTE - Jade Biosciences, Inc. - COM as of Q4 2023.
Jade Biosciences, Inc. - COM (AVTE) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.6K shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.26M shares), Sofinnova Investments, Inc. (3.76M shares), TCG Crossover Management, LLC (2.2M shares), Atlas Venture Life Science Advisors, LLC (2.04M shares), BAKER BROS. ADVISORS LP (1.68M shares), Cormorant Asset Management, LP (1.21M shares), Frazier Life Sciences Management, L.P. (1.2M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (1.06M shares), GREAT POINT PARTNERS LLC (1.04M shares), and ORBIMED ADVISORS LLC (757K shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.